The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 12 - 13, 2025

Biotech & Pharma Updates | August 12 - 13, 2025

🧬 Sarepta touts new DMD safety data (no ambulatory deaths), Vor's Sjögren's syndrome disease bet hits late stage trial success in China, Hatteras Venture Partners news $200M biotech/healthtech fund, HopeAI's partners with Mayo Clinical on AI-powered trial design, Treg takes an L as Abata Tx shutters, Generation Bio cuts 90% of staff

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | August 11 - 12, 2025

Biotech & Pharma Updates | August 11 - 12, 2025

🧬 Summit skips quarterly call as AstraZeneca deal rumors fly, Bayer + Kumquat Biosciences' up to $1.3B KRAS G12D inhibitor deal, Eli Lilly + UK gov launch obesity care access initiative, Insmed scores FDA approval for bronchiectasis therapy, FDA may deny renewed authorization for Pfizer's pediatric COVID vaccine

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | August 10 - 11, 2025

Biotech & Pharma Updates | August 10 - 11, 2025

🧬 Another Chinese biotech licensing deal (Expedition Therapeutics & Fosun Pharma), NextRNA closes shop, 10x Genomics to acquire Scale Biosciences, and BridgeBio Oncology Therapeutics completes SPAC integration

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | August 8 - 10, 2025

Biotech & Pharma Updates | August 8 - 10, 2025

🧬 Prasad's back at CBER, Strand raises $153M, FDA restricts bluebird bio's Skysona gene therapy

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | August 3 - 8, 2025 (OOO Catch-up!)

Biotech & Pharma Updates | August 3 - 8, 2025 (OOO Catch-up!)

🧬 A one-off TLDR Biotech update covering last week

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 31 - August 3, 2025

Biotech & Pharma Updates | July 31 - August 3, 2025

🧬 Sanofi buys China rights to Arrowhead's rare metabolic disease therapy, 4DMT rises on positive Ph2 DME gene therapy data, new Cayman Island-based biotech buys rights to two pre-clinical TCE assets from China's Lepu Biopharma

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 30 - 31, 2025

Biotech & Pharma Updates | July 30 - 31, 2025

🧬 AbbVie's $1B psychedelics play, Novo Nordisk's hemophilia antibody Alhemo lands FDA approval, Trump goes after big pharma with most-favored nations threats

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 29 - 30, 2025

Biotech & Pharma Updates | July 29 - 30, 2025

🧬 GSK's committed to US investment ("tens of billions" in fact), Teva not bothered by tariffs, and Biogen, Eisai present positive long-term Leqembi data in Alzheimer's disease

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 28 - 29, 2025

Biotech & Pharma Updates | July 28 - 29, 2025

🧬 FDA's big CBER shake-up, Novo Nordisk dives while AstraZeneca soars, and massive cuts coming to Merck & Co. ($3B by EOY 2027)

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 27 - 28, 2025

Biotech & Pharma Updates | July 27 - 28, 2025

🧬 MapLight's $372.5M Series D, Adaptimmune sells-out (commercial assets)

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 25 - 27, 2025

Biotech & Pharma Updates | July 25 - 27, 2025

🧬 Hengrui & GSK link-up on 12 medicines, while Roche still in it for the gene therapy long-game

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | July 23 - 24, 2025

Biotech & Pharma Updates | July 23 - 24, 2025

🧬 3-peat of CGT layoffs, Eli Lilly goes in on molecular gates (up to $856M), and FDA (likely) wants new safety studies for Sarepta's Elevidys

Anis Fahandej-Sadi
Anis Fahandej-Sadi
FirstBack
12345678
Next Last